Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Relapse is the main cause of treatment failure for leukaemia patients with unfavourable gene mutations who receive allogeneic haematopoietic stem cell transplantation (allo‐HSCT). There is no consensus on the indication of donor lymphocyte infusion (DLI) for prophylaxis of relapse after allo‐HSCT. T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Autores principales: Zhang, Rui, Wang, Lili, Chen, Peng, Gao, Xiaoning, Wang, Shuhong, Li, Fei, Dou, Liping, Gao, Chunji, Li, Yan, Liu, Daihong
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124122/
https://ncbi.nlm.nih.gov/pubmed/33932107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3763
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares